A dual-action combination of Cagrilintide (amylin analog) and Semaglutide (GLP-1 agonist) being researched for enhanced weight management effects through complementary mechanisms.
1 independent Janoshik purity test cover CAGRILINTIDE + SEMAGLUTIDE across 1 vendor.
Category: Weight Loss & Metabolic. Evidence rating: D (animal/preclinical only).
Clinical status: Preclinical
Combines amylin-mediated satiety and gastric effects with GLP-1 receptor activation for dual metabolic pathway targeting.
Safety considerations: Limited safety data available; Not approved for human use.
Reviewed by the PeptideAtlas Editorial Team.
| Vendor | Best tested purity |
|---|
Related peptides: Eloralintide.
A dual-action combination of Cagrilintide (amylin analog) and Semaglutide (GLP-1 agonist) being researched for enhanced weight management effects through complementary mechanisms.
CAGRILINTIDE + SEMAGLUTIDE has been studied for: Enhanced weight management, Dual mechanism approach, Appetite control. Dual-action blend targeting multiple metabolic pathways.
Combines amylin-mediated satiety and gastric effects with GLP-1 receptor activation for dual metabolic pathway targeting.
CAGRILINTIDE + SEMAGLUTIDE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.